Phase III Study of AK112 for NSCLC Patients
A phase 3 trial of Ivonescimab, Pemetrexed, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Summit Therapeutics, active and no longer recruiting.
Overview
Phase III Study of AK112 for NSCLC Patients is a phase 3 interventional study registered as NCT06396065 by Summit Therapeutics, with 420 participants enrolled, started 2023-05-04 and due to reach its primary completion in 2025-04-12. Interventions recorded: AK112 Injection, Placebo Injection. Conditions listed: Non-Squamous Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialClinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Shares Summit Therapeutics, Ivonescimab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialAnti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metas
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialAK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
Shares Ivonescimab, Pemetrexed, Carboplatin, Small-cell lung cancer.
- TrialAK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
Shares Ivonescimab, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.